Literature DB >> 1495540

Anaphylactic shock after retreatment with OKT3 monoclonal antibody.

D Abramowicz, A Crusiaux, M Goldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1495540     DOI： 10.1056/NEJM199209033271018

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 2.  The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors:  Lara Marks
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 3.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

Review 4.  Mechanisms and functional implications of intestinal barrier defects.

Authors:  Le Shen; Liping Su; Jerrold R Turner
Journal:  Dig Dis       Date:  2009-11-04       Impact factor: 2.404

Review 5.  Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.

Authors:  Vicente Planelles; Frank Wolschendorf; Olaf Kutsch
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

Review 6.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

7.  Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.

Authors:  Takao Shishido; Frank Wolschendorf; Alexandra Duverger; Frederic Wagner; John Kappes; Jennifer Jones; Olaf Kutsch
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

8.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

Review 9.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

10.  Monoclonal antibodies and Fc fragments for treating solid tumors.

Authors:  Andrea M Eisenbeis; Stefan J Grau
Journal:  Biologics       Date:  2012-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.